Razpis: Preclinical Drug Discovery

Funding for promising preclinical drug discovery and biomarker development programmes relevant to Alzheimer's disease, other dementias and cognitive ageing.

datum: 20.09.2017

kategorija: novice

Slika_Alzheimer

Financer: Alzheimer's Drug Discovery Foundation

Največja vrednost projekta: 150.000,00 EUR/leto; ADDF dopušča možnost večletnih projektov in dodatnih financiranj

Upravičenost kandidatov: javne in zasebne pravne osebe, profitne in neprofitne organizacije, vključno z akademskimi ustanovami in biotehnološkimi podjetji, ne glede na lokacijo

Rok za prijavo: 17. 11. 2017

Prijava: preko spletne strani ADDF

---

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) provides funding to leading scientists who are conducting the most promising, innovative Alzheimer's drug research worldwide.

The ADDF aims to plug the translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive ageing.

The ADDF's Preclinical Drug Discovery scheme works through three mechanisms:

Terms and Conditions

2015 Preclinical Research Funding Priorities:

With regards to potential drug targets:

Programme areas of particular interest include: